The types and characteristics of FcγRs. Source: Sino Biological Inc. To mediate antibody-dependent cellular cytotoxicity (ADCC), NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA).

NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an ...

granting the latter exclusive rights to leverage its antibody sequence in the chimeric antigen receptor T cell (CAR-T) and chimeric antigen receptor natural killer cell (CAR-NK) therapy research ...

Aslan also discusses how NK cell therapy can work in conjunction with monoclonal antibodies to produce an even more effective therapy. He also takes a step back to look at what the future of cell ...

Assets generated by the platform engage the CD16A receptor found on NK cells and macrophages at an epitope which is differentiated from the binding site of monoclonal antibodies. The result is ...

The results are a further endorsement of the potential of Innate’s antibody-based NK cell engager therapeutics (ANKET) platform, which attracted a €400 million partnership with Sanofi in 2016 ...

SENTI-202, an off-the-shelf, logic-gated, CAR natural killer cell therapy drove complete remission of pretreated blood cancers in a first-in-human trial, according to results presented by Stephen ...

Our other products for T cell activation and expansion: GMP Grade anti-CD3 Antibody, GMP Grade Anti-human CD3/CD28 magnetic beads, GMP Grade IL-2, IL-7, IL-15, IL-21, etc. 2. Enhance NK cell ...

The most successful programs, antibody–drug conjugates ... on innate immune cells—a population that includes natural killer (NK) cells and macrophages—and a tumor surface protein such ...

Several patients with acute myeloid leukemia (AML) who were treated with SENTI-202, a chimeric antigen receptor natural killer (CAR-NK ... treat with cell-based therapies and antibodies.